Inhibitors of poly(ADP-ribose) polymerase (PARP) were first approved for ovarian cancer treatment in 20149, and are now part of the standard of care for maintenance therapy in the first-line and recurrence settings for this disease5,6,8,10. The gene discussed is PARP1; the disease is ovarian carcinoma.